Levosimendán Ever Pharma

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendán Ever Pharma (Levosimendan)

Q: What is Levosimendán Ever Pharma used for?

Levosimendán Ever Pharma contains levosimendan, an intravenous cardiac inotropic agent used primarily to treat acute decompensated heart failure. It improves heart muscle contractility and reduces vascular resistance, helping patients with severe, sudden worsening of heart failure symptoms.

Q: How does levosimendan work in the body?

Levosimendan enhances myocardial contractility by sensitizing troponin C to calcium, allowing stronger heart contractions without raising intracellular calcium. It also opens ATP‑dependent potassium channels in vascular smooth muscle, causing vasodilation that lowers preload and afterload, together supporting cardiac output.

Q: What is the usual dose of levosimendan?

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s condition, weight, and response. It is administered as an intravenous infusion, and the exact rate and duration are individualized and outlined in the product’s prescribing information.

Q: Is levosimendan safe during pregnancy or breastfeeding?

Safety data for levosimendan in pregnancy and lactation are limited, and the product’s pregnancy category is unknown. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

Q: How do I order Levosimendán Ever Pharma from GNH India?

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Q: How does levosimendan compare with other inotropic agents?

Unlike traditional catecholamine inotropes, levosimendan increases contractility without raising intracellular calcium, reducing the risk of arrhythmias. It also provides vasodilation through potassium‑channel opening, offering combined inotropic and afterload‑reducing effects, which can be advantageous over agents like dobutamine in certain acute heart‑failure scenarios.

Q: What are the storage and handling requirements for this product?

Levosimendán Ever Pharma should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. The solution should be kept in its original packaging until use to maintain stability and potency.

Q: How is levosimendan administered?

Levosimendan is given as an intravenous infusion. After a loading dose (if prescribed), a continuous infusion is typically administered over several hours under close hemodynamic monitoring in a hospital setting.

Q: What are the most serious risks associated with levosimendan?

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Continuous cardiac and blood‑pressure monitoring is essential during infusion to detect and manage these potential complications promptly.

Q: Who should not receive levosimendan?

Levosimendan is contraindicated in patients with severe hypotension (systolic BP < 90 mmHg), uncontrolled arrhythmias, or known hypersensitivity to the drug. Caution is also advised in severe renal or hepatic impairment, and it should be avoided in patients receiving other potent vasodilators without careful monitoring.

Levosimendan, the active ingredient in Levosimendán Ever Pharma, is a calcium sensitizer / K‑ATP channel opener presented as an intravenous solution for intravenous use. It is indicated for the treatment of acute decompensated heart failure in adult patients.
GNH India supplies Levosimendán Ever Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Ever Valinject Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is used in the management of acute cardiac conditions that require inotropic support and vasodilation.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion.
Cardiogenic shock (when used under specialist supervision): provides inotropic support while reducing afterload.
Heart failure with reduced ejection fraction during acute decompensation: enhances myocardial contractility without increasing intracellular calcium load.

How It Works

Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby enhancing myocardial contractility without raising intracellular calcium concentrations. Simultaneously, it opens ATP‑dependent potassium channels in vascular smooth muscle, causing vasodilation and reducing cardiac preload and afterload, which together improve cardiac performance in acute heart failure.

Side Effects

Levosimendan may be associated with several adverse reactions.

Common Side Effects

Headache: mild to moderate intensity.
Hypotension: transient drop in blood pressure.
Nausea or vomiting: gastrointestinal discomfort.
Dizziness or light‑headedness: related to blood pressure changes.
Tachycardia: increased heart rate.
Arrhythmias: occasional premature beats.

Serious or Rare Side Effects

Severe hypotension: may require intervention.
Ventricular arrhythmias: potentially life‑threatening.
Myocardial ischemia: chest pain or ECG changes.
Allergic reactions: rash, pruritus, or anaphylaxis.
Liver enzyme elevation: increased ALT/AST.
Electrolyte disturbances: especially potassium shifts.

Precautions & Warnings

Levosimendan should be administered with careful clinical monitoring.

Cardiac monitoring: continuous ECG and hemodynamic assessment during infusion.
Blood pressure monitoring: watch for hypotension, especially in patients on other vasodilators.
Renal function: adjust use in severe renal impairment.
Electrolyte balance: correct hypokalemia or hypomagnesemia before initiation.
Contraindication in severe hypotension: avoid if systolic BP < 90 mmHg.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan may interact with several drug classes, requiring attention to dosage and monitoring.

Major Interactions (Avoid)

Concurrent vasodilators (e.g., nitroglycerin, nitroprusside): risk of profound hypotension.
Other inotropes (e.g., dobutamine, milrinone): additive cardiac stimulation.
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma levels.

Moderate Interactions (Monitor Closely)

Diuretics: may exacerbate electrolyte shifts.
ACE inhibitors or ARBs: combined effect on blood pressure.
Beta‑blockers: may blunt desired inotropic response.
Calcium channel blockers: potential additive vasodilation.
Anti‑arrhythmic agents: monitor for rhythm disturbances.

Frequently Asked Questions

Levosimendán Ever Pharma contains levosimendan, an intravenous cardiac inotropic agent used primarily to treat acute decompensated heart failure. It improves heart muscle contractility and reduces vascular resistance, helping patients with severe, sudden worsening of heart failure symptoms.

Levosimendan enhances myocardial contractility by sensitizing troponin C to calcium, allowing stronger heart contractions without raising intracellular calcium. It also opens ATP‑dependent potassium channels in vascular smooth muscle, causing vasodilation that lowers preload and afterload, together supporting cardiac output.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s condition, weight, and response. It is administered as an intravenous infusion, and the exact rate and duration are individualized and outlined in the product’s prescribing information.

Safety data for levosimendan in pregnancy and lactation are limited, and the product’s pregnancy category is unknown. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility without raising intracellular calcium, reducing the risk of arrhythmias. It also provides vasodilation through potassium‑channel opening, offering combined inotropic and afterload‑reducing effects, which can be advantageous over agents like dobutamine in certain acute heart‑failure scenarios.

Levosimendán Ever Pharma should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. The solution should be kept in its original packaging until use to maintain stability and potency.

Levosimendan is given as an intravenous infusion. After a loading dose (if prescribed), a continuous infusion is typically administered over several hours under close hemodynamic monitoring in a hospital setting.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Continuous cardiac and blood‑pressure monitoring is essential during infusion to detect and manage these potential complications promptly.

Levosimendan is contraindicated in patients with severe hypotension (systolic BP < 90 mmHg), uncontrolled arrhythmias, or known hypersensitivity to the drug. Caution is also advised in severe renal or hepatic impairment, and it should be avoided in patients receiving other potent vasodilators without careful monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.